Title |
A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms. |
Authors |
Cornu C, Mercier C, Ginhoux T, Masson S, Mouchet J, Nony P, Kassai B, Laudy V, Berquin P, Franc N, Le Heuzey MF, Desombre H, Revol O. |
Journal |
Eur Child Adolesc Psychiatry. |
Year |
2018 |
Vol (Issue) |
27(3) |
Page |
377-84. |
doi |
10.1007/s00787-017-1058-z. |
PMID |
28993963 |
Url |
http://www.ncbi.nlm.nih.gov/pubmed/28993963 |
MeSH |
Adolescent
Attention Deficit Disorder with Hyperactivity/drug therapy*
Child
Double-Blind Method
Fatty Acids, Omega-3/pharmacology
Fatty Acids, Omega-3/therapeutic use*
Female
Humans
Male
Treatment Outcome |
Keywords |
Child ADHD; Omega-3 rich fatty acid supplementation; Randomized controlled trial |
한글 키워드 |
어린이 ADHD; 오메가-3 지방산 보충제; 무작위배정 비교 임상시험 |
KMCRIC Summary & Commentary |
KMCRIC 비평 보기 + |
Korean Study |
|
Abstract |
OBJECTIVE:
Clinical trials and inconclusive meta-analyses have investigated the effects of omega-3 supplements in children with Attention-Deficit Hyperactivity Disorder (ADHD). We performed a randomised placebo-controlled trial to evaluate the efficacy of omega-3 fatty acids.
METHODS:
Children aged 6-15 years with established diagnosis of ADHD were randomised 1:1 to receive either supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) or a placebo for 3 months. Psychotropic or omega-3-containing treatments were not authorised during the study. The primary outcome was the change in the Attention-Deficit Hyperactivity Disorder Rating Scale version 4 (ADHD-RS-IV). Other outcomes included safety, lexical level (Alouette test), attention (Test of Attentional Performance for Children-KiTAP), anxiety (48-item Conners Parent Rating Scale-Revised-CPRS-R), and depression (Children's Depression Inventory-CDI).
RESULTS:
Between 2009 and 2011, 162 children were included in five French child psychiatry centres. The mean age was 9.90 (SD 2.62) years and 78.4% were boys. The inclusion ADHD-RS-IV at was 37.31 (SD 8.40). The total ADHD-RS-IV score reduction was greater in the placebo group than in the DHA-EPA group: -19 (-26, -12) % and -9.7 (-16.6, -2.9) %, respectively, p = 0.039. The other components of the Conners score had a similar variation but the differences between groups were not significant. Two patients in the DHA-EPA group and none in the placebo group experienced a severe adverse event (hospitalisation for worsening ADHD symptoms).
CONCLUSION:
This study did not show any beneficial effect of omega-3 supplement in children with mild ADHD symptoms. |
국문초록 |
|
Language |
영어 |
첨부파일 |
|